aTyr Pharma Cuts 60% of Workforce, CFO and GC Depart, in Pivot to Efzofitimod for ILD

summarizeSummary

aTyr Pharma announced a 60% workforce reduction, the departure of its CFO and General Counsel, and a strategic pivot to focus on efzofitimod in ILD. The company reported $58.9 million in cash and a runway into late 2028, but will need additional funding for its planned Phase 3 trial.

check_boxKey Events · Executive and Board Changes · ATYR

• 60% Workforce Reduction

  To align resources with the efzofitimod program in ILD, aTyr is cutting approximately 60% of its workforce — a drastic cost-saving measure.

• CFO and GC Departures

  Effective September 30, 2026, CFO Jill Broadfoot and General Counsel Nancy Denyes will step down and transition to consulting roles. VP of Finance Brandon Yaras will assume the CFO position on October 1, 2026.

• $13M Annual Cost Savings

  Beginning in Q4 2026, the restructuring and additional cost-saving measures are expected to reduce annualized operating expenses by approximately $13 million.

• Cash Runway into Late 2028

  As of June 30, 2026, cash, cash equivalents, restricted cash and investments totaled $58.9 million, providing a runway into late 2028 based on current operations. Additional capital will be needed for the planned Phase 3 study.

auto_awesomeAnalysis · ATYR · Life Sciences

In a sweeping restructuring to preserve capital and sharpen its focus, aTyr Pharma is eliminating 60% of its workforce and replacing both its CFO and General Counsel. The entire effort now centers on efzofitimod, its lead candidate for interstitial lung disease. With $58.9 million in cash at the end of Q2, the company has a runway into late 2028, though additional funding will be required for the planned Phase 3 trial. Annualized operating expenses are expected to drop by roughly $13 million starting in Q4 2026. This is a survival move that fundamentally reshapes the cost structure and leadership team, underscoring both the urgency and the high-stakes bet on efzofitimod's success.